Connect your AI

Boston Scientific BSX Litigation payment exclusion from EBITDA

Other financials

Income statement

Revenue$5.2B+11.6%

Gross profit$3.6B+12.6%

Operating income$1.1B+19.5%

Net income$1.3B+99.3%

EPS (diluted)$0.90+100%

Balance sheet

Cash & equivalents$850.0M+146%

Total equity$25.9B+16.4%

Total assets$44.4B+10.5%

Cash flow

Operating cash flow$348.0M-35.7%

CapEx$177.0M-5.4%

Free cash flow$171.0M-51.7%

Valuation

Market cap$67.32B-37.5%

P/E18.9×-34.3×

P/S3.3×-2.9×

Profitability

Gross margin69.2%+0.5pp

Operating margin18.4%+2.2pp

Net margin17.3%+5.7pp

Returns & leverage

Return on equity14.8%+5.2pp

Debt / equity0×-0.5×

Current ratio1.9×+0.4×

Where this comes from

Reported directly by Boston Scientific in its filing.

Tagged under the XBRL concept bsx:LitigationPaymentExclusionFromEBITDA.

The official record: Boston Scientific’s 10-Q, filed May 1, 2026, on SEC EDGAR. View the filing →

Ask your AI about Boston Scientific's litigation payment exclusion from ebitda.

Connect your AI assistant and see it in context, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Boston Scientific's litigation payment exclusion from EBITDA?: Boston Scientific (BSX) reported litigation payment exclusion from EBITDA of $1.16B in Q1 2026.
How has Boston Scientific's litigation payment exclusion from EBITDA changed year-over-year?: Boston Scientific's litigation payment exclusion from EBITDA increased by 16.0% year-over-year, from $1B to $1.16B.